Effector Therapeutics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
EFTR
- Investments
-
1
Effector Therapeutics General Information
Description
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).
Contact Information
Website
www.effector.comCorporate Office
- 142 North Cedros Avenue
- Suite B
- Solana Beach, CA 92075
- United States
Corporate Office
- 142 North Cedros Avenue
- Suite B
- Solana Beach, CA 92075
- United States
Effector Therapeutics Timeline
Effector Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 7.74K |
Effector Therapeutics Financials Summary
As of 31-Mar-2024, Effector Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 55,235 | 32,902 | 5,174 | 299,301 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (32,610) | (33,753) | (20,800) | 17,580 |
| Net Income | (34,631) | (35,811) | (22,665) | 15,798 |
| Total Assets | 27,131 | 20,544 | 29,077 | 54,056 |
| Total Debt | 20,248 | 20,545 | 20,281 | 20,030 |
Effector Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Effector Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Effector Therapeutics Comparisons
Industry
Financing
Details
Effector Therapeutics Competitors (47)
One of Effector Therapeutics’s 47 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Celyad Oncology | Formerly VC-backed | Mont-Saint-Guibert, Belgium | ||||
| Halozyme Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Effector Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Effector Therapeutics Patents
Effector Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3206158-A1 | Solid forms of an eif4e inhibitor | Pending | 22-Dec-2020 | ||
| US-12655161-B2 | Solid forms of an eif4e inhibitor | Active | 22-Dec-2020 | ||
| US-20240076301-A1 | Solid forms of an eif4e inhibitor | Active | 22-Dec-2020 | ||
| WO-2022137174-A1 | Solid forms of an eif4e inhibitor | Inactive | 22-Dec-2020 | ||
| US-20250243221-A1 | Covalent modifiers of eif4e inhibiting compounds | Pending | 27-May-2020 | C07D519/00 |
Effector Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Effector Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Effector Therapeutics Acquisitions (1)
Effector Therapeutics’s most recent deal was a Merger/Acquisition with Locust Walk Acquisition. The deal was made on 25-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Locust Walk Acquisition | 25-Aug-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Effector Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Effector Therapeutics FAQs
-
When was Effector Therapeutics founded?
Effector Therapeutics was founded in 2012.
-
Where is Effector Therapeutics headquartered?
Effector Therapeutics is headquartered in Solana Beach, CA.
-
What is the size of Effector Therapeutics?
Effector Therapeutics has 25 total employees.
-
What industry is Effector Therapeutics in?
Effector Therapeutics’s primary industry is Biotechnology.
-
Is Effector Therapeutics a private or public company?
Effector Therapeutics is a Public company.
-
What is Effector Therapeutics’s stock symbol?
The ticker symbol for Effector Therapeutics is EFTR.
-
Who are Effector Therapeutics’s competitors?
Genetix Biotherapeutics, Regenxbio, Celyad Oncology, Halozyme Therapeutics, and CRISPR Therapeutics are some of the 47 competitors of Effector Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
